Genotoxicity Regulation Research Trials 
The Pharma Data
MARCH 25, 2021
These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. lead researcher and Professor in Breast Cancer Excellence in the Perelman School of Medicine at the University of Pennsylvania.
Pharmaceutical Technology
SEPTEMBER 10, 2008
was established in 1999 in the process of privatisation of the State Research Institute for Pharmacy and Biochemistry in the Czech Republic. ” New projects we have been involved with have helped the company to accelerate its development in the field of pre-clinical research. .” Dr Ivana Surovà: Biotest s.r.o.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
FEBRUARY 8, 2021
IBRANCE is an oral inhibitor of CDKs 4 and 6, 1 which are key regulators of the cell cycle that trigger cellular progression. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% IBRANCE may impair fertility in males and has the potential to cause genotoxicity. About IBRANCE® (palbociclib) 125 mg tablets and capsules.
Drug Discovery World
MAY 10, 2023
While the discovery phase – which includes target discovery, target validation, lead compound identification, and lead compound optimisation – averages several years and $200 million, the majority of the research, time, and financial spend takes place downstream in drug development.
The Pharma Data
MAY 13, 2021
Experimental Diabetes Research. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. The trans-fat ban–food regulation and long-term health. Exposure to sorbitol during lactation causes metabolic alterations and genotoxic effects in rat offspring.
Expert insights. Personalized for you.
52 
Let's personalize your content